Early-life wheezing-associated infections with rhinovirus (RV) have been associated with asthma development in children. We have shown that RV infection of 6-day-old mice induces mucous metaplasia and airways hyperresponsiveness, which is dependent on IL-13, IL-25, and type 2 innate lymphoid cells (ILC2s). Infection of immature mice fails to induce lung IFN-g expression, in contrast to mature 8-week-old mice with a robust IFN-g response, consistent with the notion that deficient IFN-g production in immature mice permits RV-induced type 2 immune responses. We therefore examined the effects of intranasal IFN-g administration on RVinduced ILC2 expansion and IL-13 expression in 6-day-old BALB/c and IL-13 reporter mice. Airway responses were assessed by histology, immunofluorescence microscopy, quantitative polymerase chain reaction, ELISA, and flow cytometry. Lung ILC2s were also treated with IFN-g ex vivo. We found that, compared with untreated RV-infected immature mice, IFN-g treatment attenuated RV-induced IL-13 and Muc5ac mRNA expression and mucous metaplasia. IFN-g also reduced ILC2 expansion and the percentage of IL-13-secreting ILC2s. IFN-g had no effect on the mRNA or protein expression of IL-25, IL-33, or thymic stromal lymphoprotein. Finally, IFN-g treatment of sorted ILC2s reduced IL-5, IL-13, IL-17RB, ST2, and GATA-3 mRNA expression. We conclude that, in immature mice, IFN-g inhibits ILC2 expansion and IL-13 expression in vivo and ex vivo, thereby attenuating RV-induced mucous metaplasia. These findings demonstrate the antagonistic function of IFN-g on ILC2 expansion and gene expression, the absence of which may contribute to the development of an asthma-like phenotype after early-life RV infection.
Recent studies suggest that type 2 innate lymphoid cells (ILC2s) play a direct role in the development of allergic airway responses. The "innate cytokines" IL-25 (or IL-17E) (1) (2) (3) (4) , IL-33 (1-3, 5, 6) , and thymic stromal lymphoprotein (TSLP) (6) each induce activation and production of type 2 cytokines from ILC2s.
Early-life respiratory viral infection, particularly rhinovirus (RV) infection, is a risk factor for asthma development in children (7, 8) . To study this, we exposed 6-day-old immature mice to RV1B, a minor group virus that infects mouse cells in vitro (9, 10) and in vivo (11) . We found that neonatal RV infection induced persistent mucous metaplasia and airways hyperresponsiveness, which was dependent on the type 2 cytokine IL-13 (12) . More recently, we showed that RV-induced mucous metaplasia and airways hyperresponsiveness were dependent on airway epithelial cell IL-25 production and expansion of IL-13-producing ILC2s (13) . Airway responses were blocked by neutralizing antibody against IL-25.
The newborn immune system is skewed toward type 2 responses. Neonatal T cells and monocytes demonstrate deficient IFN-g production (14) (15) (16) , as well as diminished responses to IFN-g stimulation (17, 18) . Accordingly, we found that IFN-g production was suppressed in RV-infected immature 6-day-old mice in comparison with 21-day-old and mature 8-week-old mice (13) . Infants with reduced blood mononuclear cell production of IFN-g, the principal type 1 cytokine, have been shown to be at a greater risk of recurrent virus-induced wheezing and asthma development (19) (20) (21) (22) . On this basis, we hypothesized that deficient IFN-g production in immature mice permits RV-induced type 2 immune responses. To test this, we examined the effects of IFN-g on RV-induced ILC2 expansion and IL-13 production in immature mice.
Materials and Methods
Generation of RV and Infection of Immature Mice RV1B (ATCC, Manassas, VA) was partially purified from infected HeLa cell lysates by ultrafiltration using a 100-kD cutoff filter and titered by plaque assay (10, 11) . BALB/c and C.129S4(B6)-Il13 tm1(YFP/cre)Lky /J mice expressing yellow fluorescent protein (YFP) under the control of the IL-13 reporter (2) (Jackson Laboratories, Bar Harbor, ME) were inoculated through the intranasal route under Forane anesthesia with 20 ml of RV1B (2 3 10 6 PFU)
or an equal volume of sham HeLa cell lysate. Selected mice were treated with intranasal IFN-g (10 ng/d) on Days 1, 3, and 5 after RV infection. Experiments were approved by the University of Michigan Institutional Animal Care and Use Committee.
Histology and Immunofluorescence Microscopy
Lungs were perfused through the pulmonary artery with phosphate-buffered saline containing 5 mM disodium ethylene diamine tetraacetate. Next, lungs were fixed with 4% paraformaldehyde overnight. Five-micrometer-thick paraffin sections were processed for histology or fluorescence microscopy, as described (23 analyzed on an LSR Fortessa (BD Biosciences, San Jose, CA). For analysis of intracellular IL-13, fresh aliquots of isolated cells from lung-minced tissues were stimulated for 5 hours with a cellstimulation cocktail (40.5 mM phorbol 12-myristate 13-acetate, 670 mM ionomycin, 5.3 mM brefeldin A, and 1 mM monensin; eBioscience), fixed, permeabilized, and incubated with antimouse IL-13 clone eBio13A (eBioscience). Alexa 488-conjugated anti-GFP (Biolegend) was used to detect the intracellular YFP.
Clinical Relevance

Harvesting of Lung ILC2s
To study lung ILC2s ex vivo, lung cells were stained with biotin-conjugated antibodies for lineage markers (CD3e, TCRb, B220/CD45R, Ter-119, Gr-1/Ly-6G/Ly-6C, CD11b, CD11c, F4/80, and FceRIa) and mixed with antibiotin microbeads (Miltenyi Biotech, Auburn, CA). The cell mixture was then subjected to a MACS Separator (Miltenyi Biotech). The flow-through was collected for fluorescence-activated cell sorting. Lineage-negative CD25 and CD127 double-positive ILC2s were sorted at 30,000 cells/ml into 12-well plates and primed with media and IL-2 (50 ng/ml) in the presence or absence of IFN-g (10 ng/ml) for 24 hours. After priming, IL-25 (20 ng/ml) or IL-33 (20 ng/ml) was added for 24 hours to activate ILC2s.
Real-Time Quantitative Polymerase Chain Reaction
Lung or ILC2 RNA was extracted with Trizol method (Invitrogen, Carlsbad, CA), with the combination of on-column digestion of genomic DNA (Qiagen, Valencia, CA). Complementary DNA was synthesized from 1 mg of RNA and subjected to quantitative real-time polymerase chain reaction by using specific mRNA primers for IFN-g, TNF-a, IL-13, IL-5, IL-25, IL-33, TSLP, IL-1b, IFN-b, Muc5ac, IL17RB, ST2, and GATA-3 (see Table E1 in the online supplement). For each sample, the level of gene expression was normalized to its own glyceraldehyde-3-phosphate dehydrogenase mRNA.
Quantitative one-step real-time polymerase chain reaction for positivestrand viral RNA was conducted using RV-specific primers and probes (forward primer: 59-GTG AAG AGC CSC RTG TGC T-39; reverse primer: 59-GCT SCA GGG TTA AGG TTA GCC-39; probe: 59-FAM-TGA GTC CTC CGG CCC CTG AAT G-TAMRA-39) (24) . Copy numbers of positive-strand viral RNA were normalized to 18S RNA, which was similarly amplified using gene-specific primers and probes. 
Data Analysis
Data are represented as mean 6 SE. Statistical significance was assessed by unpaired t test or one-way analysis of variance, as appropriate. Group differences were pinpointed by the Newman-Keuls multiple comparison test.
Results
Attenuated Type 1 Response in RV-Infected Neonatal Mice
We infected 6-day-old and 8-week-old mice with RV1B and analyzed cytokine mRNA expression. In contrast to mature mice, RV infection of neonatal mice did not induce increased expression of the type 1 cytokines IFN-g and TNF-a (Figure 1 ). On the other hand, the type 2 cytokine genes IL-5 and IL-13 were induced in immature mice but not in mature mice. mRNA expression of the innate cytokines IL-25 and IL-33, each of which has been implicated in ILC2 expansion (1-6), were also increased in RV-infected immature mice, but not in mature mice. These results confirm that early-life RV infection elicits exaggerated type 2 responses while failing to induce a typical type 1 antiviral response. Finally, RV infection increased IL-1b and IFN-b mRNA expression in both immature and adult mice.
IFN-g Reduces Mucous Metaplasia in RV-Infected Neonatal Mice
In our previous report, we found that RV infection of neonatal mice induced mucous metaplasia and airways hyperresponsiveness, which was dependent on the type 2 cytokine IL-13 (12, 13) . In this study, we hypothesized that IFN-g counteracts the observed asthma phenotype. PBS or IFN-g was delivered intranasally 1, 3, and 5 days after RV infection of 6-day-old mice. There was no PAS staining in the noncartilaginous airways of sham-infected, PBS-treated animals ( Figure 2A ). All RV-infected, PBStreated mice showed PAS staining of the airway epithelium, indicative of mucous metaplasia, although there was significant individual variability in the response to infection. Finally, IFN-g treatment of mice after RV infection nearly abolished airway PAS staining. Lung mRNA expression of IL-13 and the mucus-related gene Muc5ac each increased with RV infection but were inhibited with IFN-g ( Figure 2B ). We also found that IFN-g decreased RV-induced mRNA expression of the IL-25 receptor IL-17RB, suggesting To exclude IFN-g-mediated antiviral responses as a cause of the observed changes, we examined viral load in the presence or absence of IFN-g. In contrast to PBS-treated mice, there was no significant effect of IFN-g on viral copy number 1-3 days after RV infection (Figure 3 ).
IFN-g Inhibits Expansion of IL-13-Expressing ILC2s in RV-Infected Immature Mice
RV infection of 6-day-old mice expands the population of ILC2s, a major source of IL-13 after RV infection (13) . We questioned whether IFN-g suppresses the expansion of ILC2s. We collected lungs 2 weeks after sham or RV infection and analyzed ILC2s using flow cytometry. We gated on small, live lineage-negative cells using a mixture of hematopoietic lineage markers (CD3e, TCRb, B220, Ter-119, Gr-1, CD11b, CD11c, F4/80, and FceRIa) ( Figure 4A ). After gating on the lineage-negative population, a discrete population of CD25 and CD127 double-positive ILC2s was found. RV infection significantly increased the number of lineage-negative CD25 1 CD127 1 cells ( Figure 4A ). IFN-g treatment decreased the ILC2 percentage and number.
For analysis of intracellular IL-13, fresh aliquots of lung mince were stimulated for 5 hours with a cell-stimulation cocktail and stained with anti-IL-13. IFN-g reduced the percentage of IL-13-expressing Lin-negative, CD25-positive cells and IL-13-expressing Linnegative CD127-positive cells ( Figure 4A ). In addition, IFN-g reduced the number of IL-13 1 CD25 2 CD127 2 double-positive cells ( Figure 4B ). Finally, IFN-g significantly decreased RV-induced IL-13 production ( Figure 4C ). Taken together, these results suggest that IFN-g suppresses RV-induced expansion of IL-13-expressing ILC2s.
We also examined the effect of IFN-g on IL-13-expressing ILC2s using IL-13 reporter mice expressing YFP under control of the IL-13 promoter to track IL-13 transcription. After RV infection, a discrete population of CD25 and CD127 double-positive ILC2s was found (see Figures E1A and E1B in the online supplement). As in BALB/c mice, expansion of the lung ILC2 population was decreased in IL-13 reporter mice treated with IFN-g after RV infection. Further analysis showed that RV infection increased the percentage of Lin-negative, CD25
1 and Lin-negative, CD127
1 cells expressing YFP ( Figures E1C and E1D) . Finally, YFPexpressing Lin-negative, CD25
1 cells were significantly reduced after IFN-g treatment, suggesting that IFN-g blocks transcription from the IL-13 promoter in lung ILC2s.
RV-Induced Expression of EpithelialDerived Innate Cytokines Is Not Inhibited by IFN-g
We showed previously that epithelial IL-25 is increased in RV-infected immature mice and is required for the development of mucus metaplasia and airways hyperresponsiveness (13) . IL-33 and TSLP may also contribute to the development of allergic airway inflammation by inducing the activation and production of type 2 cytokines from ILC2s (1-3, 5, 6 ). We therefore questioned whether expression of IL-25, IL-33, or TSLP is inhibited by IFN-g. Consistent with our previous report, IL-25 mRNA and protein expression was increased in RV-infected 6-day-old mice ( Figures 5A and 5B ). There was no reduction of IL-25 mRNA in the presence of IFN-g. RV also increased protein but not mRNA levels of IL-33 and TSLP. There was no effect of IFN-g on either mRNA or protein expression of IL-33 or TSLP. Lung immunofluorescent staining showed increased IL-25 protein abundance after RV infection, which was unaffected by IFN-g ( Figure 5C ). Quantification of IL-25 immunofluorescence by National Institutes of Health ImageJ software showed no significant effect of IFN-g on airway IL-25 expression. Taken together, these results show that IFN-g does not block RV-induced mucous metaplasia in immature mice by inhibiting the expression of epithelial-derived innate cytokines IL-25, IL-33, or TSLP.
IFN-g Inhibits ILC2 Gene Expression
To better assess the effect of IFN-g on ILC2 maturation and function, we sorted ILC2s and cultured them in the presence or absence of IFN-g ex vivo. Lineage-negative, CD25-and CD127-double-positive ILC2s were sorted from the lungs of RV-infected baby mice. As reported previously (1-3), in combination with IL-2, RV increased ILC2 mRNA expression of IL-13, IL-5, the IL-25 receptor IL-17RB, the IL-33 receptor ST2, and GATA-3 ( Figure 6A ). Treatment of IFN-g suppressed ILC2 gene expression. TNF-a mRNA expression was not regulated by IL-25 or IFN-g treatment. IL-33-induced mRNA expression was also suppressed by IFN-g ( Figure 6B ). Finally, IFN-g abolished IL-25-and IL-33-induced IL-13 protein expression, as well as IL-25-induced IL-5 protein expression ( Figure 6C ). These results suggest that IFN-g has an inhibitory effect on ILC2 maturation and function.
Discussion
The immature immune system is qualitatively different from the adult immune system in that it is refractory to type 1 and permissive to type 2 responses. Neonatal T cells and monocytes demonstrate specific deficiencies in IFN-g production (14) (15) (16) . Secretion of the type 1 cytokine IL-12 p35 is suppressed in neonatal dendritic cells, thereby inhibiting the ability to elicit T-cell IFN-g production (25) (26) (27) (28) . Sp1 transcription factor binding to a positioned nucleosome (nuc-2) within the IL-12(p35) gene promoter is severely impaired in neonatal dendritic cells because of a defect in chromatin remodeling (27) . We therefore reasoned that immature mice infected with RV would demonstrate a type 2 immune response, in contrast to mature mice, which demonstrate a normal type 1 viral response. Accordingly, we found that IFN-g production was suppressed in RV-infected immature 6-day-old mice in comparison with 21-day-old and 8-week-old mice (13) . RV infection of immature mice also induced persistent mucous metaplasia and airways hyperresponsiveness, which was dependent on airway epithelial cell IL-25 production and expansion of IL-13-producing ILC2s (13) . We further hypothesized that deficient IFN-g production in immature mice permits RVinduced type 2 immune responses. To test this, we examined the effects of IFN-g on RV-induced ILC2 expansion and IL-13 production in immature mice. In both wildtype and IL-13 reporter mice, IFN-g blocked RV-induced ILC2 expansion and IL-13 transcription in vivo. IFN-g treatment reduced the gene expression of cultured ILC2s in response to IL-25 or IL-33. These results demonstrate that IFN-g negatively regulates both ILC2 expansion and gene expression. Furthermore, restoration of IFN-g prevents the development of the asthma phenotype, establishing IFN-g deficiency as a cause of viral-induced allergic disease in immature animals.
Our data confirm new reports showing that IFN-g inhibits ILC2 expansion and gene expression in response to helminth infection (31, 32) . In addition, ILC2 function was noted recently to be increased in type 1 IFN receptor-null mice infected with attenuated influenza A virus (33) , demonstrating that type 1 IFNs also negatively regulate ILC2s. Type 1 IFN-mediated inhibition of ILC2 proliferation and cytokine release occurred independently of STAT4, T-bet, iNOS, and STAT6 but required STAT1, STAT2, and IRF9. Our study extends the latter report by showing that a physiologic state of IFN deficiency (i.e., immaturity) also permits virus-induced ILC2-mediated type 2 immunopathology.
Because RV-induced airway responses in 6-day-old mice require virus replication (13) , it is possible that IFN-g attenuates ILC2 responses by inhibiting viral replication. Inhibition of viral replication by IFN-g is required for disease resistance to encephalomyocarditis virus (34) and Theiler's murine encephalomyelitis virus (35) . However, IFN-g administration had no effect on rhinoviral copy number, suggesting that the antiviral function of IFN-g did not account for the attenuated ILC2 response. Similarly, airway epithelial cell-derived IL-25 is required for IL-13-dependent mucous metaplasia and airways hyperresponsiveness in RV-infected immature mice (13) and for respiratory syncytial virus-induced Th2 responses in natural killer cell-deficient mice (36) , suggesting the possibility that IFN-g attenuates type 2 responses by blocking IL-25. However, RV-induced lung IL-25 mRNA and protein expression was not reduced in the presence of IFN-g. On the contrary, we found, we believe for the first time, that IFN-g blocks ILC2 mRNA expression of the IL-25 receptor IL-17RB, consistent with the notion that IFN-g blocks the sensitivity of ILC2s to IL-25 secretion. Finally, there was no effect of IFN-g on the mRNA or protein expression of IL-33 and TSLP, each of which may also regulate the production of type 2 cytokines from ILC2s (1-3, 5, 6) . Together, these data show that IFN-g does not block the development of the mucous metaplasia phenotype by inhibiting the expression of epithelial-derived innate cytokines.
A shift in the Th1/Th2 cytokine balance toward a type 1 profile may contribute to protection against asthma and allergy. Peripheral blood monocytes from children and adults with asthma produce lower levels of IFN-g in response to allergen when compared with cells from control individuals (37, 38) . IFN-g levels are increased in allergic patients after immunotherapy (39, 40) . Infants with reduced blood mononuclear cell production of IFN-g, the principal type 1 cytokine, have been shown to be at a greater risk of recurrent virus-induced wheezing and asthma development (19) (20) (21) (22) . IFN-g production by stimulated cord blood mononuclear cells is a negative predictor of allergic disorders including asthma (19) . Lower blood mononuclear cell IFN-g production at the time of bronchiolitis has been related to the development of asthma (20) . Impaired IFN-g production at 3 months significantly increases the risk of developing recurrent wheezing in the first year of life (21) . Newborns with measurable peripheral blood monocyte IFN-g responses to respiratory viral infection are less likely to develop recurrent virusinduced wheezing than are those without such responses (22) . It is therefore conceivable that, in early life, deficient IFN-g production after respiratory viral infection may lead to an aberrant type 2 response favorable to asthma development, particularly in genetically susceptible individuals, when maintained by appropriate stimuli.
Unlike Th2 cells, ILC2s do not express acquired antigen receptors or undergo clonal selection and expansion when stimulated. Still, mature ILC2s express the characteristic surface receptors and effector molecules of differentiated T-cell subsets (41, 42) . Like Th2 cells, both human and mouse ILC2s express high levels of GATA-3, and GATA-3 is essential for ILC2 development and Th2 cell cytokine production (43) (44) (45) (46) . Our ex vivo study showed reduced GATA-3 mRNA expression in IFN-g-treated ILC2s, suggesting a novel mechanism by which IFN-g may inhibit ILC2 proliferation and cytokine release.
Conclusions
We conclude that IFN-g treatment inhibits the development of an asthma phenotype in RV-infected immature mice by suppressing the expansion of IL-13-expressing ILC2s. Further characterization of this cellular immune pathway may lead to the identification of molecular and cellular targets for the prevention of asthma. n
